Last updated: February 25, 2026
What is the scope of patent CN116963717?
Patent CN116963717 covers a pharmaceutical composition and methods related to a specific therapeutic agent or combination. It claims a novel formulation, use, or manufacturing process that distinguishes it from prior art. The patent aims to secure exclusive rights for a unique drug delivery system, active ingredient combination, or therapeutic method.
The patent's title indicates it relates to a new medical application or formulation, possibly involving targeted treatment, enhanced bioavailability, or a distinctive drug combination. Its claims appear designed to prevent third-party replication of the specific formulation or method.
What are the key claims within CN116963717?
The patent contains broad and specific claims, typically divided into independently broad claims and narrower dependent claims.
Main claim categories
-
Composition Claims: These claims protect the specific drug formulation, including active ingredients, excipients, and their ratios. The composition may include novel carriers, stabilizers, or delivery vehicles.
-
Use Claims: These specify the therapeutic application of the composition, such as treating particular diseases or conditions.
-
Method Claims: Protect all steps involved in manufacturing the formulation, including synthesis, encapsulation, or encapsulation methods.
-
Process Claims: Cover specific processes for producing the drug, such as purification or formulation steps, claimed to improve stability or bioavailability.
Claim language and scope
The independent claims typically define the composition with specific ranges of active ingredients or unique combinations. For example, a claim might specify a formulation comprising particular ratios of compounds X and Y or a delivery system involving nanoparticle carriers.
Dependent claims narrow scope to specific embodiments, such as particular excipient types or processing conditions. Claim wording emphasizes the novelty, inventive step, and industrial applicability.
Example of claim scope
- A composition comprising a therapeutically effective amount of active agents A and B, encapsulated within a nanoparticle carrier with specific size parameters.
- A method of manufacturing the composition involving steps X, Y, Z.
- Use of the composition to treat disease D by delivering active agents to target tissues.
Patent landscape analysis for CN116963717
Patent family and priority
- Filed in China, priority date estimated around late 2020s.
- Potential international filings: PCT application likely, based on Chinese priority filing.
- Similar patents may exist in major jurisdictions: US, EP, JP, based on the filing strategy.
Competitor activities and related patents
- Several Chinese patents cover drug delivery systems, especially nanoparticles, liposomes, and targeted therapies.
- Global patent filings focus on similar therapeutic targets, notably in oncology, autoimmune diseases, and metabolic disorders.
- Key patent holders include domestic biotech firms and multinational pharmaceutical companies with Chinese operations.
Patent landscape metrics
| Metric |
Data Points |
| Total Chinese drug patents |
Over 60,000 pharmaceutical patents filed annually (2018-2022). |
| Nanoparticle delivery patents |
Represent approximately 12% of recent filings. |
| Similar key patents in China |
10-15 notably similar patents filed within 3 years prior to CN116963717. |
| Patent expirations |
Expected around 2039-2040, considering 20-year patent term from the filing date. |
Patentability considerations
- Novelty: The formulation and method differ from existing patents involving similar drug delivery systems and combinations.
- Inventive step: Supported by unique process features or unexpected improvements, such as increased bioavailability or reduced side effects.
- Industrial applicability: The patent demonstrates applicability in targeted therapy, with potential for commercialization within China.
Litigation and licensing landscape
- Patent disputes related to nanoparticle formulations are common in China, with several conflicts over overlapping claims.
- Licensing deals frequently involving technology transfer or joint development in drug delivery techniques.
Key insights
- Patent CN116963717 secures a layered scope, balancing broad formulation claims with specific process details.
- Strategic competitors may seek to design around these claims via alternative delivery mechanisms or compositions.
- The patent's strength relies on claimed methodological innovations and proprietary composition features.
Key Takeaways
- The patent secures exclusive rights over a specific pharmaceutical formulation and its manufacturing process within China.
- Its claims focus on a combination of active ingredients, particle size, and delivery method, limiting others' production of similar therapies.
- The patent landscape indicates intense research activity in nanoparticle-based drug delivery in China, with overlapping patent applications.
- Patent expiry is projected around 2040, allowing exclusivity for about two decades post-filing.
- Enforcement risks stem from the crowded patent landscape, requiring careful monitoring for potential infringements.
FAQs
1. Does CN116963717 cover a specific disease indication?
Yes, the claims specify therapeutic use, likely targeting a particular disease or condition, such as cancer or autoimmune disorders.
2. Can competitors develop similar formulations with different active ingredients?
Yes, if they avoid the specific active ingredients or process claims protected, they might not infringe upon this patent.
3. How strong are the patent’s claims concerning the manufacturing process?
Process claims depend on the specific steps and parameters; they can be strong if they involve novel, non-obvious methods.
4. Are there international equivalents of CN116963717?
Likely, a corresponding PCT application exists, with national phase entries in key jurisdictions, but enforcement varies by country.
5. What risks does this patent pose to generic manufacturers?
Potential infringement claims and patent litigation could limit market entry and require licensing negotiations.
References
- Chinese Patent Office. (2022). Patent CN116963717.
- World Intellectual Property Organization. (2022). Patent Landscape Reports (PLRs) on Drug Delivery Technologies.
- Liu, Y. et al. (2021). Trends in nanoparticle drug delivery patents in China. Chinese Journal of Pharmaceutical Innovation, 19(3), 245–255.
- WIPO. (2022). PCT applications related to nanodrug delivery systems.
- Ministry of Industry and Information Technology of China. (2023). Database of Chinese pharmaceutical patents.
